Searched for
RANBAXY INDIA
Sun Pharma to acquire Organon for $11.75 billion in India’s biggest pharma dealSun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acq...- Sun's strong gravity helps India Inc's pullSun Pharma has expanded its horizons by acquiring Organon, a notable New Jersey pharmaceutical firm. This strategic acquisition fortifies S...
- Sun Pharma: How a small Kolkata trader became a global buyout artistSun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...
- ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...
- Alkem Labs CEO Vikas Gupta may exit companyAlkem Labs, a leading Indian drug maker, is set for a top management change. Vikas Gupta, the CEO for nearly three years, is expected to de...
- Ranbaxy India head Rajeev Sibal latest to quitSibal, a pharma industry veteran, is expected to join drug company Lupin later this month.
- Sun Pharma to push Ranbaxy's OTC brands like Revital, Volini, ChericofAccording to top executives from both the companies, Ranbaxy's OTC portfolio is going to be one of the key segments for Sun Pharma with sig...
- Ranbaxy slips nearly 5% as US pulls approval for AstraZeneca and Roche drugsThe FDA has stripped Ranbaxy of tentative approval and six-month exclusivity for a copy of Roche Holding AG's antiviral Valcyte, a fresh bl...
- Sun Pharma-Ranbaxy deal: Daichi Sankyo failed to harness the complexities of a strong generic business, says Malvinder SinghThe Sun-Ranbaxy combined entity will unlock the true potential of the Gurgaon based company, says former Ranbaxy owner Malvinder Singh.
- USFDA raises concerns over Ranbaxy's Toansa plantThe US Food and Drug Administration's observations regarding the manufacturing practices in the company's plant in Punjab.
- Our current drugs in India, global markets safe: RanbaxyRanbaxy today claimed that its "products currently in the Indian market and globally are safe and efficacious".
- Mylan sues USFDA for allowing Ranbaxy to sell Diovan's generic versionMylan has sued USFDA for not allowing it to market a generic version of medicine Diovan, saying that Ranbaxy has lost its exclusivity for t...
- Ranbaxy may take Rs 2,500-cr m-t-m hit on forex contractsRanbaxy, India’s largest drugmaker by sales, may be sitting on mark-to-market (MTM) losses of over Rs 2,500 crore on foreign currency deriv...
- Daiichi to meet US FDA to resolve Ranbaxy issueDaiichi Sankyo, the Japanese pharmaceutical company that bought Ranbaxy Laboratories last year, will meet US FDA officials next month to so...
- Daiichi to meet FDA, launches 1st drug through RanbaxyDaiichi Sankyo, the new owner of Ranbaxy Laboratories will meet US Food and Drugs Administration (FDA) officials next month to sort out the...
- Ranbaxy initiates studies on respiratory inflammation moleculeIndia's largest drugmaker Ranbaxy Laboratories has initiated initial (Phase I) clinical studies on the lead compound for respiratory inflam...
- US FDA blocks imports from Ranbaxy for poor qualityFDA move does not end US sales by Ranbaxy. The factories with defects are in Dewas and Paonta Sahib. The Top 10 food myths revealed | Bewar...
- Daiichi & Ranbaxy will rank at number 15 globally: Takashi ShodaRanbaxy Laboratories will be the Indian counterpart of Daiichi Sankyo. Whatever we do in India will be done through Ranbaxy.
- Ranbaxy to ink R&D deal with foreign coClose on the heels of striking a strategic alliance with domestic pharma company Orchid, Ranbaxy is close to signing a significant research...
- Indian drug makers eye US firm Par PharmaIndia's top drug makers are in the race to acquire US-based generic drug maker, Par Pharmaceutical Co Inc, two Indian newspapers reported o...
Load More
